We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alternative-Splicing Database Launched in Europe

By Biotechdaily staff writers
Posted on 23 May 2003
A major European initiative in the post-genomics field highlights the importance of alternative RNA splicing, the mechanism that enables the cell to generate several distinct proteins from a single gene. More...
Called the Alternative Splicing Database (ASD), the initiative aims to build a unique human database of all the alternatively spliced genes to develop new diagnostic tools for major diseases such as cancer, neurodegeneration, and infertility.

The ASD brings together seven members from Germany, Spain, France, Israel, and the UK with complementary expertise and know-how. The consortium includes biologists involved in data collection and chip optimization and design as well as computer scientists working on data mining and user-friendly data interfaces. The ASD will run for three years. As part of the project, the data on alternative exons from human, mouse, drosophila, and rat that have already been published in peer-reviewed journals will be collected and integrated into a computer database that can be accessed by researchers and doctors. In addition, the ASD consortium will develop DNA microarrays that contain cDNAs of all the splicing regulatory proteins and their isoforms, as well as chips that incoporate a number of disease-relevant genomic signatures for cancer, neurodegeneration, and infertility. These chips will then be used to test an individual's predisposition and to diagnose these diseases.

"Not only will the ASD project allow us to investigate alternatively spliced variants associated with human diseases, but it will also enable study of the pathologic changes of factors regulating alternative splicing,” said ASD coordinator Dr. Stefan Stamm, of the Institute of Biochemistry, University Erlangen-Nuremberg (Germany). "This is of great importance in order to maximize the value of the large scientific initiatives such as the human genome and proteome projects.”




Related Links:
U. of Erlangen-Nuremberg

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.